Data and product needs for influenza immunization programs in low- and middle-income countries: Rationale and main conclusions of the WHO preferred product characteristics for next-generation influenza vaccines

Vaccine

Volumn 35, Issue 43, 2017, Pages 5734-5737

  Neuzil, Kathleen M ^a   Bresee, Joseph S ^b   de la Hoz, Fernando ^c   Johansen, Kari ^d   Karron, Ruth A ^e   Krishnan, Anand ^f   Madhi, Shabir A ^g   Mangtani, Punam ^h   Spiro, David J ⁱ   Ortiz, Justin R ^j  

^a UNIVERSITY OF MARYLAND   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c Colombian National Institute of Health ^*  (Colombia)

^d EUROPEAN CENTRE FOR DISEASE PREVENTION AND CONTROL ECDC   (Sweden)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^g UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^h LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

ⁱ NATIONAL INSTITUTES OF HEALTH   (United States)

^j WORLD HEALTH ORGANIZATION   (Switzerland)

more..

Author keywords

Global health; Influenza vaccine; Vaccine development; World Health Organization

Indexed keywords

INFLUENZA VACCINE;

CLINICAL OUTCOME; DISEASE SEVERITY; DRUG MANUFACTURE; HEALTH CARE DELIVERY; HEALTH CARE NEED; HEALTH CARE SYSTEM; HEALTH PROGRAM; HUMAN; INFLUENZA; INFLUENZA VACCINATION; LOW INCOME COUNTRY; MIDDLE INCOME COUNTRY; NOTE; PRIORITY JOURNAL; PUBLIC HEALTH; WORLD HEALTH ORGANIZATION; IMMUNOLOGY; POVERTY; PREVENTIVE HEALTH SERVICE; PROCEDURES; VACCINATION;

HUMANS; IMMUNIZATION PROGRAMS; INFLUENZA VACCINES; INFLUENZA, HUMAN; POVERTY; PUBLIC HEALTH; VACCINATION; WORLD HEALTH ORGANIZATION;

EID: 85028888451     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2017.08.088     Document Type: Note

References (12)

1. World Health Organization. Vaccines against influenza WHO position paper – November 2012. Releve epidemiologique hebdomadaire. 2012;87:461–76.
2. Palache, A., Oriol-Mathieu, V., Fino, M., Xydia-Charmanta, M., Seasonal influenza vaccine dose distribution in 195 countries (2004–2013): little progress in estimated global vaccination coverage. Vaccine 33 (2015), 5598–5605.
3. Ortiz, J.R., Perut, M., Dumolard, L., Wijesinghe, P.R., Jorgensen, P., Ropero, A.M., et al. A global review of national influenza immunization policies: analysis of the 2014 WHO/UNICEF Joint Reporting Form on immunization. Vaccine 34 (2016), 5400–5405.
4. World Health Organization. WHO Preferred Product Characteristics for Next-Generation Influenza Vaccines. In: Organization WH, editor. Geneva, Switzerland: World Health Organization; 2017.
5. World Health Organization, WHO Preferred Product Characteristics (PPCs). 2017, World Health Organization.
6. Osterholm, M.T., Kelley, N.S., Sommer, A., Belongia, E.A., Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 12 (2012), 36–44.
7. World Health Organization. Global vaccine action plan 2011-2020. 2013.
8. World Health Organization, Preferred Product Characteristics for Next Generation Influenza Vaccines. 2017, World Health Organization, Geneva License: CC BY-NC-SA 3.0 IGO. Available at: http://apps.who.int/iris/bitstream/10665/258767/1/9789241512466-eng.pdf.
9. Centers for Disease Control and Prevention, Estimates of deaths associated with seasonal influenza – United States, 1976–2007. MMWR Morbidity Mortality Weekly Rep 59 (2010), 1057–1062.
10. Gessner, B.D., Brooks, W.A., Neuzil, K.M., Vernet, G., Bright, R.A., Tam, J.S., et al. Vaccines as a tool to estimate the burden of severe influenza in children of low-resourced areas (November 30-December 1, 2012, Les Pensieres, Veyrier-du-Lac, France). Vaccine 31 (2013), 3222–3228.
11. World Health Organization. Assessing the Programmatic Suitability of Vaccine Candidates for WHO prequalification (WHO/IVB/12.10). In: Organization WH, editor. Geneva, Switzerland: World Health Organization; 2012.
12. Cox NJ, Hickling J, Jones R, Rimmelzwaan GF, Lambert LC, Boslego J, et al. Report on the second WHO integrated meeting on development and clinical trials of influenza vaccines that induce broadly protective and long-lasting immune responses: Geneva, Switzerland, 5–7 May 2014.